Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H12N2O3.ClH |
| Molecular Weight | 220.653 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC)C(=O)NC(=O)NC1=O
InChI
InChIKey=SACKVYGWWZDWQS-UHFFFAOYSA-N
InChI=1S/C8H12N2O3.ClH/c1-3-8(4-2)5(11)9-7(13)10-6(8)12;/h3-4H2,1-2H3,(H2,9,10,11,12,13);1H
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
|
| Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
| Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The chronic hepatic or renal toxicity of di(2-ethylhexyl) phthalate, acetaminophen, sodium barbital, and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with carcinogenesis or tumor promotion. | 1988 Dec |
|
| Effects of sodium salts of phenobarbital and barbital on development of bladder tumors in male F344/NCr rats pretreated with either N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-nitrosobutyl-4-hydroxybutylamine. | 1989 Apr |
|
| Stability of thiopental and pentobarbital in human plasma determined with a new easy and specific gas chromatography-mass spectrometry assay. | 1999 Aug |
|
| Determination of barbiturates in urine by micellar liquid chromatography and direct injection of sample. | 1999 Nov |
|
| Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon. | 2001 |
|
| Ellipsometric in vitro studies on blood plasma and serum adsorption to zirconium. | 2001 Nov |
|
| The effects of some porphyrinogenic drugs on the brain cholinergic system. | 2002 Feb |
|
| Immunoelectrophoresis of red blood cells performed on microcapillary chips. | 2002 Jul |
|
| Complexation of phenolic guests by endo- and exo-hydrogen-bonded receptors. | 2003 Jul 21 |
|
| The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
| Heme oxygenase, aminolevulinate acid synthetase and the antioxidant system in the brain of mice treated with porphyrinogenic drugs. | 2005 Oct 3 |
|
| Proximal visceral endoderm and extraembryonic ectoderm regulate the formation of primordial germ cell precursors. | 2007 Dec 20 |
|
| Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus. | 2008 Jan 2 |
|
| Application of two different kinds of sera against the Proteus penneri lipopolysaccharide core region in search of epitopes determining cross-reactions with antibodies. | 2008 Mar-Apr |
|
| EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. | 2008 May |
|
| Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. | 2008 Nov |
|
| Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. | 2009 Apr |
|
| Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. | 2009 Feb |
|
| The glyceraldehyde-3-phosphate dehydrogenase and the small GTPase Rab 2 are crucial for Brucella replication. | 2009 Jun |
|
| Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. | 2009 Sep |
|
| Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. | 2010 |
|
| Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. | 2010 Aug 20 |
|
| Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. | 2010 Feb 5 |
|
| Determining the reactivity and titre of serum using a haemagglutination assay. | 2010 Jan 29 |
|
| The virulence protein SopD2 regulates membrane dynamics of Salmonella-containing vacuoles. | 2010 Jul 15 |
|
| Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation. | 2010 Jul 20 |
|
| Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. | 2010 Jun 7 |
|
| Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells. | 2010 Mar 16 |
|
| Effects of 17beta-oestradiol and norethisterone acetate on sulfonation and sialylation of gonadotrophins in post-menopausal women. | 2010 May |
|
| Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. | 2010 May 27 |
|
| A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. | 2010 Oct 20 |
|
| Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. | 2010 Oct 20 |
|
| Modulation of polymorphonuclear neutrophil functions by astrocytes. | 2010 Sep 9 |
Patents
Sample Use Guides
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
22163315
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY | |||
|
23851-27-6
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY | |||
|
48Q3695ASR
Created by
admin on Sat Dec 16 18:30:11 GMT 2023 , Edited by admin on Sat Dec 16 18:30:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
